1. Home
  2. NRSN vs RDI Comparison

NRSN vs RDI Comparison

Compare NRSN & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.85

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

RDI

Reading International Inc

HOLD

Current Price

$1.07

Market Cap

23.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRSN
RDI
Founded
2017
1937
Country
Israel
United States
Employees
16
2005
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
23.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NRSN
RDI
Price
$0.85
$1.07
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
138.1K
22.8K
Earning Date
03-31-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$16.25
Revenue Next Year
$583.67
$4.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.94
52 Week High
$2.60
$1.65

Technical Indicators

Market Signals
Indicator
NRSN
RDI
Relative Strength Index (RSI) 57.00 44.10
Support Level $0.85 $1.01
Resistance Level $1.06 $1.16
Average True Range (ATR) 0.07 0.04
MACD -0.00 -0.00
Stochastic Oscillator 53.65 16.67

Price Performance

Historical Comparison
NRSN
RDI

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: